Key result
Heart failure with preserved ejection fraction lacks disease-specific therapies, with current management relying on volume control and comorbidity management.
Management of HFpEF currently relies on symptom control with diuretics and management of comorbidities such as hypertension, highlighting the need for targeted therapies.
Heart failure with preserved ejection fraction accounts for up to 50% of hospitalized heart failure patients and is associated with significant mortality and morbidity. The pathophysiology is heterogeneous and not very well defined, which explains the lack of disease-specific therapies. The principles of treating heart failure with preserved ejection fraction are controlling volume with diuretics and diet, and controlling the comorbidities, mainly the hypertension. Further research is encouraged to ascertain the key components of the disease that will serve as targets for therapy.
No takes yet. Share an insight, caveat, or question.
Alsamara et al. (2014) conducted a review in Heart failure with preserved ejection fraction. Heart failure with preserved ejection fraction lacks disease-specific therapies, with current management relying on volume control and comorbidity management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: